School of Medicine
Showing 1-10 of 40 Results
Christopher Beaulieu M.D., Ph.D.
Professor of Radiology (Musculoskeletal Imaging) and, by courtesy, of Orthopaedic Surgery
Current Research and Scholarly InterestsInformatics and image processing techniques that provide infrastructure for diagnosis in musculoskeletal imaging. Decision support for improving accuracy of bone tumor diagnosis. Improved methods for MRI in the musculoskeletal system.
Hans-Christoph Becker, MD, FSABI, FSCCT
Clinical Professor, Radiology
Current Research and Scholarly InterestsMyocardial bridges (MB) with associated upfront atherosclerotic lesions are common findings on coronary computed tomography angiography (CTA). Abnormal septal wall motion in exercise echocardiography (EE) may to be associated with MB. Intravascular ultrasound (IVUS) is considered the gold standard for the detection of MB. We investigate whether CTA is comparable to IVUS for the assessment of MB and upstream plaques in symptomatic patients with suspicion for MB raised by EE.
Associate Professor of Radiology (Pediatric Radiology) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsStudies on apoptotic cell death in vivo using the H MRS phenomenon.
Associate Professor of Radiology (Pediatric Radiology)
Current Research and Scholarly InterestsUltrasonic beamforming, imaging methods, systems, and devices.
The J.G. Jackson and C.J. Wood Professor of Chemistry
BioProfessor Dai’s research spans chemistry, physics, and materials and biomedical sciences, leading to materials with properties useful in electronics, energy storage and biomedicine. Recent developments include near-infrared-II fluorescence imaging, ultra-sensitive diagnostic assays, a fast-charging aluminum battery and inexpensive electrocatalysts that split water into oxygen and hydrogen fuels.
Born in 1966 in Shaoyang, China, Hongjie Dai began his formal studies in physics at Tsinghua U. (B.S. 1989) and applied sciences at Columbia U. (M.S. 1991). He obtained his Ph.D. from Harvard U and performed postdoctoral research with Dr. Richard Smalley. He joined the Stanford faculty in 1997, and in 2007 was named Jackson–Wood Professor of Chemistry. Among many awards, he has been recognized with the ACS Pure Chemistry Award, APS McGroddy Prize for New Materials, Julius Springer Prize for Applied Physics and Materials Research Society Mid-Career Award. He has been elected to the American Academy of Arts and Sciences, National Academy of Sciences (NAS), National Academy of Medicine (NAM) and Foreign Member of Chinese Academy of Sciences.
The Dai Laboratory has advanced the synthesis and basic understanding of carbon nanomaterials and applications in nanoelectronics, nanomedicine, energy storage and electrocatalysis.
The Dai Lab pioneered some of the now-widespread uses of chemical vapor deposition for carbon nanotube (CNT) growth, including vertically aligned nanotubes and patterned growth of single-walled CNTs on wafer substrates, facilitating fundamental studies of their intrinsic properties. The group developed the synthesis of graphene nanoribbons, and of nanocrystals and nanoparticles on CNTs and graphene with controlled degrees of oxidation, producing a class of strongly coupled hybrid materials with advanced properties for electrochemistry, electrocatalysis and photocatalysis. The lab’s synthesis of a novel plasmonic gold film has enhanced near-infrared fluorescence up to 100-fold, enabling ultra-sensitive assays of disease biomarkers.
Nanoscale Physics and Electronics
High quality nanotubes from his group’s synthesis are widely used to investigate the electrical, mechanical, optical, electro-mechanical and thermal properties of quasi-one-dimensional systems. Lab members have studied ballistic electron transport in nanotubes and demonstrated nanotube-based nanosensors, Pd ohmic contacts and ballistic field effect transistors with integrated high-kappa dielectrics.
Nanomedicine and NIR-II Imaging
Advancing biological research with CNTs and nano-graphene, group members have developed π–π stacking non-covalent functionalization chemistry, molecular cellular delivery (drugs, proteins and siRNA), in vivo anti-cancer drug delivery and in vivo photothermal ablation of cancer. Using nanotubes as novel contrast agents, lab collaborations have developed in vitro and in vivo Raman, photoacoustic and fluorescence imaging. Lab members have exploited the physics of reduced light scattering in the near-infrared-II (1000-1700nm) window and pioneered NIR-II fluorescence imaging to increase tissue penetration depth in vivo. Video-rate NIR-II imaging can measure blood flow in single vessels in real time. The lab has developed novel NIR-II fluorescence agents, including CNTs, quantum dots, conjugated polymers and small organic dyes with promise for clinical translation.
Electrocatalysis and Batteries
The Dai group’s nanocarbon–inorganic particle hybrid materials have opened new directions in energy research. Advances include electrocatalysts for oxygen reduction and water splitting catalysts including NiFe layered-double-hydroxide for oxygen evolution. Recently, the group also demonstrated an aluminum ion battery with graphite cathodes and ionic liquid electrolytes, a substantial breakthrough in battery science.
Professor of Radiology (General Radiology) and, by courtesy, of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsAs a physician-scientist involved in the care of pediatric patients and developing novel pediatric molecular imaging technologies, my goal is to link the fields of nanotechnology and medical imaging towards more efficient diagnoses and image-guided therapies. Our research team develops novel imaging techniques for improved cancer diagnosis, for image-guided-drug delivery and for in vivo monitoring of cell therapies in children and young adults.
Professor of Radiology (Body Imaging) and, by courtesy, of Bioengineering
Current Research and Scholarly Interests1. MRI of Breast Cancer, particularly new techniques. Currently being explored are techniques including ultra high spatial resolution MRI and contrast-agent-free detection of breast tumors.
2. MRI-guided interventions, especially MRI-compatible remote manipulation and haptics
3. Medical Mixed Reality. Currently being explored are methods of fusing patients and their images to potentially improve breast conserving surgery, and other conditions.
Adam de la Zerda
Associate Professor of Structural Biology and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsMolecular imaging technologies for studying cancer biology in vivo
Professor of Radiology (Canary Cancer Center) and, by courtesy, of Electrical Engineering
BioUtkan Demirci is a tenured professor in the School of Medicine at Stanford University and serves as the Interim Division Chief and Director of the Canary Center at Stanford for Cancer Early Detection in the Department of Radiology. Prior to Stanford, he was an Associate Professor of Medicine at the Brigham and Women’s Hospital, Harvard Medical School, and a faculty member of the Harvard-MIT Health Sciences and Technology division.
Professor Demirci received his PhD from Stanford University in Electrical Engineering in 2005 and holds M.S. degrees in Electrical Engineering, and in Management Science and Engineering. He has published over 200 peer-reviewed journal articles, 24 book chapters, 7 edited books, and several hundred abstracts and proceedings, as well as having over 25 patents and disclosures pending or granted. He has mentored and trained hundreds of successful scientists, entrepreneurs and academicians and fostered research and industry collaborations around the world. Dr. Demirci was awarded the NSF CAREER Award, and IEEE EMBS Early Career Award. He is currently a fellow of the the American Institute for Medical and Biological Engineering (AIMBE, 2017), and Distinguished Investigator of the Academy for Radiology and Biomedical Imaging Research and serves as an editorial board member for a number of peer-reviewed journals.
The BAMM Lab group focuses on developing innovative extracellular vesicle isolation tools, point-of-care technologies and creating microfluidic platforms for early cancer detection with broad applications to multiple diseases including infertility and HIV. Dr. Demirci’s lab has collaborated with over 50 research groups and industry partners around the world. His seminal work in microfluidics has led to the development of innovative FDA-approved platform technologies in medicine and many of his inventions have been industry licensed. He holds several FDA-approved and CE-marked technologies that have been widely used by fertility clinics with assisted reproductive technologies leading to over thousands of live births globally and in the US.
Dr. Demirci is a serial academic entrepreneur and co-founder of DxNow, Zymot, Levitas Bio, Mercury Biosciences and Koek Biotech and serves as an advisor, consultant and/or board member to some early stage companies and investment groups.
Professor of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsMy focus is image-guided drug and gene delivery and I am engaged in the design of imaging devices, molecularly-targeted imaging probes and engineered delivery vehicles, drawing upon my education in biology and imaging physics and more than 20 years of experience with the synthesis and labeling of therapeutic particles. My laboratory has unique resources for and substantial experience in synthetic chemistry and ultrasound, CT, MR and PET imaging.